比較慢性透析病患使用血管收縮素轉化脢抑制劑或血管收縮素受體阻斷劑與其他抗高血壓藥物之間的差異

以作者查詢圖書館館藏

、以作者查詢臺灣博碩士

、以作者查詢全國書目

、勘誤回報

、線上人數：44

、訪客IP：18.119.139.50

姓名

蕭惠璘(Hui-Lin Hsiao) 查詢紙本館藏

畢業系所

系統生物與生物資訊研究所

論文名稱

比較慢性透析病患使用血管收縮素轉化脢抑制劑或血管收縮素受體阻斷劑與其他抗高血壓藥物之間的差異
(Comparisons of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers with other Antihypertensive Agents on Chronic Dialysis Patients)

相關論文

★ miRCSC : miRNA表現量伴隨癌症改變狀態的文獻證明搜尋引擎	★ 利用上下文感知最大化邊界神經網路提取疾病與疾病的關聯
★ 應用嵌入式系統於呼吸肌肉群訓練儀之系統開發	★ 勃起障礙與缺血性心臟病的雙向研究: 以台灣全人口基礎的世代研究
★ 基質輔助雷射脫附飛行時間式串聯質譜儀微生物抗藥性資料視覺化工具	★ 使用穿戴式裝置分析心律變異及偵測心律不整之應用程式
★ 建立一個自動化分析系統用來分析任何兩種疾病之間的關聯性透過世代研究設計以及使用承保抽樣歸人檔	★ 青光眼病患併發糖尿病,使用Metformin及Sulfonylurea治療得到中風之風險:以台灣人口為基礎的觀察性研究
★ 利用組成識別和序列及空間特性構成之預測系統來針對蛋白質交互作用上的特殊區段點位進行分析及預測辨識	★ 新聞語意特徵擷取流程設計與股價變化關聯性分析
★ 藥物與疾病關聯性自動化分析平台設計與實作	★ 建立財務報告自動分析系統進行股價預測
★ 建立一個分析疾病與癌症關聯性的自動化系統	★ 基於慣性感測器虛擬鍵盤之設計與實作
★ 一個醫療照護監測系統之實作	★ 應用手機開發手握球握力及相關資料之量測

檔案

[Endnote RIS 格式]

[Bibtex 格式]

[相關文章]

[文章引用]

[完整記錄]

[館藏目錄]

[檢視]

[下載]

本電子論文使用權限為同意立即開放。
已達開放權限電子全文僅授權使用者為學術研究之目的，進行個人非營利性質之檢索、閱讀、列印。
請遵守中華民國著作權法之相關規定，切勿任意重製、散佈、改作、轉貼、播送，以免觸法。

摘要(中)

背景
透析病患因心血管疾病死亡的比例是一般沒有腎臟衰竭病人的10-20 倍。對於透析病患，
高血壓是併發心血管疾病及腦血管疾病重要的危險因子。大約有80%的慢性透析病人有高血壓，
所以挑選適當的高血壓治療藥物很重要。血管收縮素轉化脢抑制劑及血管收縮素受體阻斷劑主
要是用來治療高血壓及心臟衰竭。最近的研究顯示，血管收縮素轉化脢抑制劑及血管收縮素受體阻斷劑對末期腎臟病患有好的療效，但是他們的效果仍不明確。因此，我們設計了回顧性的研究，去評估血管收縮素轉化脢抑制劑及血管收縮素受體阻斷劑和其他抗高血壓藥物對於慢性透析病人在長期臨床上的差異。
方法
我們使用了國家健康保險研究資料庫去做全國性的比對的事件對照研究分析。我們比對了病人的年齡、性別及糖尿病得病情形。我們的研究人口包括，2004/1/1 到2004/12/31 期間的末期腎臟病的新發個案且有高血壓的病人，病人因為服用不同的抗高血壓藥物而被分到不同群組。追縱時間是從透析開始至死亡或是至研究結束時間 (2008/12/31)。我們使用了卡方檢定、t 檢定、Kaplan-Meier 存活分析、對數等級檢定及Cox 比例風險模型做進一步的分析。
結果
這個研究包含了2262 個有高血壓的血液透析病人。在這個研究中，有251 (11.2%)人被歸類為事件組，他們服用的是血管收縮素轉化脢抑制劑或血管收縮素受體阻斷劑；有1997 (88.8%)人被歸類為控制組，他們服用的是除了血管收縮素轉化脢抑制劑或血管收縮素受體阻斷劑的其他抗高血壓藥物。基本的人口特性包括性別、年齡、共病情形及死亡率，在事件組與控制組之間基本研究人口的特性很相似，但用藥的情況 (控制組1.06 ± 0.24 及對照組1.74 ± 0.84,P<0.0001)與因腦血管疾病的住院率 (P=0.006)在事件組與控制組有差異。
結論
在五年的追蹤期裡，我們發現事件組因腦血管疾病住院的情形相較低。這些發現或許可以提供我們一些臨床的建議，有高血壓的透析病患應該優先服用血管收縮素轉化脢抑制劑及血管收縮素受體阻斷劑。

摘要(英)

Background
The risk of cardiovascular mortality in dialysis patients is 10 to 20-fold than in age-matched and
sex-matched general population without kidney damage. Hypertension is one of the most important
factors of cardiovascular and cerebrovascular complications on dialysis patients. About 80% of
dialysis patients are hypertensive, so it’s important to choose appropriate hypertensive agents.
Angiotensin-converting enzyme inhibitors (ACEI) and Angiotensin receptor blockers (ARB) were directed at treating hypertension and heart failure. Recent researches stated that ACEI and ARB were benefit on chronic dialysis patients, but the outcomes were still uncertain. Therefore, we used the retrospective study to evaluate the clinical outcome between ACEI/ARB and other antihypertensive agents on chronic dialysis patients.
Methods
We performed a retrospective matched case-control study using the population-based database from National Health Insurance Research Database (NHIRD). Patients’ age, gender and diabetes mellitus were matched. From January 2004 to December 2004, new onset end-stage renal disease patients with hypertension were included and were grouped according to different antihypertensive agents. They were followed up from the date of dialysis initiation till death or the end of the study. Chi-squared test, t-test, Kaplan-Meier survival analysis, log-rank test and Cox-proportional hazard
model were used for analysis.
Results
A total of 2262 patients having hypertension who started hemodialysis (HD) between January 2004 and December 2004 were included. There were 251 (11.2%) patients treated with ACEI /ARB in the case group and 1997 (88.8%) patients treated with other hypertensive agents in the control
group. The baseline characteristics including age, gender, comorbidities and mortality between two
groups are similar except the kinds of hypertensive agents (1.06 ± 0.24 in case group, 1.74 ± 0.84 in control group, p<0.0001) and lower hospitalization rate of cerebrovascular disease (CVA) in case group (P =0.0061).
Conclusions
In the five-year follow-up, we found that case group has a lower hospitalization rate in CVA than control group. However, hospitalization rate of other factors and all cause mortality rate showed lower significant difference. Such findings may provide clinical implication about ACEI/ARB on
hypertensive dialysis patients.

關鍵字(中)

★ 腦血管疾病
★ 心血管疾病
★ 血液透析
★ 末期腎臟病
★ 血管收縮素受體阻斷劑
★ 血管收縮素轉化脢抑制劑

關鍵字(英)

★ Angiotensin-converting enzyme inhibitors
★ Angiotensin receptor blockers
★ End-stage renal disease
★ Hemodialysis
★ Cerebrovascular disease
★ Cardiovascular disease

論文目次

摘要 ........................................................................................................................................................ i
Abstract ................................................................................................................................................iii
List of Figures ..................................................................................................................................... vii
List of Tables ......................................................................................................................................viii
Chapter 1 Introduction ........................................................................................................................... 1
1-1 Background .............................................................................................................................. 1
1-2 Motivation ............................................................................................................................... 2
1-3 Goals ....................................................................................................................................... 2
Chapter 2 Related Works ....................................................................................................................... 3
2-1 End-Stage Renal Disease ......................................................................................................... 3
2-2 ACEI and ARB ........................................................................................................................ 3
Chapter 3 Materials and Methods .......................................................................................................... 4
3-1 Database .................................................................................................................................. 4
3-2 NHIRD Filed Selection ........................................................................................................... 4
3-3 Definitions of Cases and Controls ........................................................................................... 5
3-4 Measurements .......................................................................................................................... 6
3-5 Statistical Analysis ................................................................................................................... 9
Chapter 4 Results ................................................................................................................................ 10
4-1 Demographics of 2004-2007 ................................................................................................. 10
4-2 Demographics of 2004 ........................................................................................................... 11
Chapter 5 Discussion ........................................................................................................................... 23
5-1 Study Limitations .................................................................................................................. 23
5-2 Review of Research Findings ................................................................................................ 23
References ........................................................................................................................................... 26
Appendix ............................................................................................................................................. 28

參考文獻

[1] B. o. N. H. Insurance, "National Health Insurance Research Database."
[2] U. S. R. D. System, "2010 Annual Data Report: Atlas of End-Stage Renal
Disease in the United States," National Institutes of Diabetes, Digestive and
Kidney Disease, Bethesda, MD.
[3] W. C. Yang and S. J. Hwang, "Incidence, prevalence and mortality trends of
dialysis end-stage renal disease in Taiwan from 1990 to 2001: the impact of
national health insurance," Nephrol Dial Transplant, vol. 23, pp. 3977-82, Dec
2008.
[4] S. J. Hwang, Yang W.C., "1999 National Dialysis Surveillance in Taiwan," Acta
Nephrologica, vol. 14, pp. 139-228.
[5] C. C. Hsu, et al., "High prevalence and low awareness of CKD in Taiwan: a
study on the relationship between serum creatinine and awareness from a
nationally representative survey," Am J Kidney Dis, vol. 48, pp. 727-38, Nov
2006.
[6] I. Kolesnyk, et al., "Effects of angiotensin-converting enzyme inhibitors and
angiotensin II receptor blockers in patients with chronic kidney disease," Neth
J Med, vol. 68, pp. 15-23, Jan 2010.
[7] D. C. Wheeler, "Cardiovascular disease in patients with chronic renal failure,"
Lancet, vol. 348, pp. 1673-4, Dec 21-28 1996.
[8] A. S. Levey, et al., "Controlling the epidemic of cardiovascular disease in
chronic renal disease: what do we know? What do we need to learn? Where
do we go from here? National Kidney Foundation Task Force on
Cardiovascular Disease," Am J Kidney Dis, vol. 32, pp. 853-906, Nov 1998.
[9] J. J. de Lima, et al., "Arterial blood pressure and left ventricular hypertrophy in
haemodialysis patients," J Hypertens, vol. 14, pp. 1019-24, Aug 1996.
[10] M. M. Salem, "Hypertension in the hemodialysis population: a survey of 649
patients," Am J Kidney Dis, vol. 26, pp. 461-8, Sep 1995.
[11] R. Agarwal and A. D. Sinha, "Cardiovascular protection with antihypertensive
drugs in dialysis patients: systematic review and meta-analysis," Hypertension,
vol. 53, pp. 860-6, May 2009.
[12] H. J. Heerspink, et al., "Effect of lowering blood pressure on cardiovascular
events and mortality in patients on dialysis: a systematic review and
meta-analysis of randomised controlled trials," Lancet, vol. 373, pp. 1009-15,
Mar 21 2009.
[13] E. M. Lonn, et al., "Emerging role of angiotensin-converting enzyme inhibitors
in cardiac and vascular protection," Circulation, vol. 90, pp. 2056-69, Oct
1994.
27
[14] P. Ruggenenti, et al., "ACE inhibitors to prevent end-stage renal disease: when
to start and why possibly never to stop: a post hoc analysis of the REIN trial
results. Ramipril Efficacy in Nephropathy," Journal of the American Society of
Nephrology, vol. 12, pp. 2832-7, Dec 2001.
[15] J. P. Casas, et al., "Effect of inhibitors of the renin-angiotensin system and
other antihypertensive drugs on renal outcomes: systematic review and
meta-analysis," Lancet, vol. 366, pp. 2026-33, Dec 10 2005.
[16] "K/DOQI clinical practice guidelines for chronic kidney disease: evaluation,
classification, and stratification," Am J Kidney Dis, vol. 39, pp. S1-266, Feb
2002.
[17] J. M. Bargman, et al., "Use of ACE inhibitors or angiotensin receptor blockers
and survival in patients on peritoneal dialysis," Nephrology Dialysis
Transplantation, vol. 23, pp. 3704-3710, Nov 2008.
[18] S. Efrati, et al., "ACE inhibitors and survival of hemodialysis patients," Am J
Kidney Dis, vol. 40, pp. 1023-9, Nov 2002.
[19] R. A. Deyo, et al., "Adapting a Clinical Comorbidity Index for Use with
Icd-9-Cm Administrative Databases," Journal of Clinical Epidemiology, vol. 45,
pp. 613-619, Jun 1992.
[20] P. S. Romano, et al., "Adapting a clinical comorbidity index for use with
ICD-9-CM administrative data: differing perspectives," Journal of Clinical
Epidemiology, vol. 46, pp. 1075-9; discussion 1081-90, Oct 1993.
[21] M. E. Charlson, et al., "A new method of classifying prognostic comorbidity in
longitudinal studies: development and validation," J Chronic Dis, vol. 40, pp.
373-83, 1987.
[22] D. J. Tai, et al., "Cardiovascular effects of angiotensin converting enzyme
inhibition or angiotensin receptor blockade in hemodialysis: a meta-analysis,"
Clin J Am Soc Nephrol, vol. 5, pp. 623-30, Apr 2010.
[23] H. Suzuki, "Therapeutic efficacy of renin-angiotensin blockade in patients
receiving dialysis," Ther Adv Cardiovasc Dis, vol. 3, pp. 397-405, Oct 2009.
[24] P. H. Pun, et al., "Predictors of survival after cardiac arrest in outpatient
hemodialysis clinics," Clin J Am Soc Nephrol, vol. 2, pp. 491-500, May 2007.
[25] S. L. Seliger, et al., "Elevated risk of stroke among patients with end-stage
renal disease," Kidney International, vol. 64, pp. 603-9, Aug 2003.
[26] K. Toyoda, et al., "Stroke in patients on maintenance hemodialysis: a 22-year
single-center study," Am J Kidney Dis, vol. 45, pp. 1058-66, Jun 2005.

指導教授

洪炯宗(Jorng-Tzong Horng)

審核日期

2011-8-29

推文